Rapid validation of cancer genes in chimeras derived from established genetically engineered mouse models

BioEssays

Volumn 33, Issue 9, 2011, Pages 701-710

  Huijbers, Ivo J ^a,b   Krimpenfort, Paul ^a,b   Berns, Anton ^a,b,c   Jonkers, Jos ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cancer; Chimeras; Embryonic stem cell; Genetically engineered mouse model; Non germline models; Recombinase mediated cassette exchange

Indexed keywords

RECOMBINASE;

ALLELE; ARTICLE; BREEDING LINE; CANCER GROWTH; CANCER INCIDENCE; CANCER SIZE; CARCINOGENESIS; CELL ISOLATION; CHIMERA; CULTURE MEDIUM; DNA MODIFICATION; EMBRYONIC STEM CELL; GENE CASSETTE; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENETIC SELECTION; HUMAN; NONHUMAN; TRANSGENIC ORGANISM; TREATMENT RESPONSE; TUMOR GENE; VALIDATION PROCESS;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CHIMERA; CULTURE MEDIA; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; EMBRYONIC STEM CELLS; GENES, NEOPLASM; HUMANS; MICE; NEOPLASMS; PLURIPOTENT STEM CELLS;

EID: 80051671759     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.201100018     Document Type: Article

References (47)

1. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100: 57-70.
2. Mueller MM, Fusenig NE. 2004. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4: 839-49.
3. Walrath JC, Hawes JJ, Van Dyke T, Reilly KM. 2010. Genetically engineered mouse models in cancer research. Adv Cancer Res 106: 113-64.
4. Heyer J, Kwong LN, Lowe SW, Chin L. 2010. Non-germline genetically engineered mouse models for translational cancer research. Nat Rev Cancer 10: 470-80.
5. Hudson TJ, Anderson W, Artez A, Barker AD, et al. 2010. International network of cancer genome projects. Nature 464: 993-8.
6. Jonkers J, Berns A. 2002. Conditional mouse models of sporadic cancer. Nat Rev Cancer 2: 251-65.
7. Singh M, Lima A, Molina R, Hamilton P, et al. 2010. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol 28: 585-93.
8. Zhou Y, Rideout WM 3rd, Zi T, Bressel A, et al. 2010. Chimeric mouse tumor models reveal differences in pathway activation between ERBB family and KRAS-dependent lung adenocarcinomas. Nat Biotechnol 28: 71-8.
9. Bachoo RM, Maher EA, Ligon KL, Sharpless NE, et al. 2002. Epidermal growth factor receptor and Ink4a/Arf: Convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 1: 269-77.
10. Evers B, Speksnijder EN, Schut E, Ciampricotti M, et al. 2010. A tissue reconstitution model to study cancer cell-intrinsic and -extrinsic factors in mammary tumourigenesis. J Pathol 220: 34-44.
11. Zender L, Xue W, Zuber J, Semighini CP, et al. 2008. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135: 852-64.
12. Watters JW, Cheng C, Majumder PK, Wang R, et al. 2009. De novo discovery of a gamma-secretase inhibitor response signature using a novel in vivo breast tumor model. Cancer Res 69: 8949-57.
13. Ying QL, Wray J, Nichols J, Batlle-Morera L, et al. 2008. The ground state of embryonic stem cell self-renewal. Nature 453: 519-23.
14. Birling MC, Gofflot F, Warot X. 2009. Site-specific recombinases for manipulation of the mouse genome. Methods Mol Biol 561: 245-63.
15. Derksen PW, Liu X, Saridin F, van der Gulden H, et al. 2006. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 10: 437-49.
16. Huijbers IJ, Krimpenfort P, Chomez P, van der Valk MA, et al. 2006. An inducible mouse model of melanoma expressing a defined tumor antigen. Cancer Res 66: 3278-86.
17. Jongsma J, van Montfort E, Vooijs M, Zevenhoven J, et al. 2008. A conditional mouse model for malignant mesothelioma. Cancer Cell 13: 261-71.
18. Liu X, Holstege H, van der Gulden H, Treur-Mulder M, et al. 2007. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci USA 104: 12111-6.
19. Meuwissen R, Linn SC, Linnoila RI, Zevenhoven J, et al. 2003. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 4: 181-9.
20. Meuwissen R, Linn SC, van der Valk M, Mooi WJ, et al. 2001. Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene. Oncogene 20: 6551-8.
21. Bruggeman SW, Hulsman D, Tanger E, Buckle T, et al. 2007. Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell 12: 328-41.
22. Brook FA, Gardner RL. 1997. The origin and efficient derivation of embryonic stem cells in the mouse. Proc Natl Acad Sci USA 94: 5709-12.
23. Keller G. 2005. Embryonic stem cell differentiation: Emergence of a new era in biology and medicine. Genes Dev 19: 1129-55.
24. Silva J, Smith A. 2008. Capturing pluripotency. Cell 132: 532-6.
25. Niwa H, Ogawa K, Shimosato D, Adachi K. 2009. A parallel circuit of LIF signalling pathways maintains pluripotency of mouse ES cells. Nature 460: 118-22.
26. Sato N, Meijer L, Skaltsounis L, Greengard P, et al. 2004. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med 10: 55-63.
27. Nichols J, Silva J, Roode M, Smith A. 2009. Suppression of Erk signalling promotes ground state pluripotency in the mouse embryo. Development 136: 3215-22.
28. Buehr M, Meek S, Blair K, Yang J, et al. 2008. Capture of authentic embryonic stem cells from rat blastocysts. Cell 135: 1287-98.
29. Li P, Tong C, Mehrian-Shai R, Jia L, et al. 2008. Germline competent embryonic stem cells derived from rat blastocysts. Cell 135: 1299-310.
30. Nichols J, Jones K, Phillips JM, Newland SA, et al. 2009. Validated germline-competent embryonic stem cell lines from nonobese diabetic mice. Nat Med 15: 814-8.
31. Nagy A, Gocza E, Diaz EM, Prideaux VR, et al. 1990. Embryonic stem cells alone are able to support fetal development in the mouse. Development 110: 815-21.
32. Eakin GS, Hadjantonakis AK. 2006. Production of chimeras by aggregation of embryonic stem cells with diploid or tetraploid mouse embryos. Nat Protoc 1: 1145-53.
33. te Riele H, Maandag ER, Berns A. 1992. Highly efficient gene targeting in embryonic stem cells through homologous recombination with isogenic DNA constructs. Proc Natl Acad Sci USA 89: 5128-32.
34. Tong C, Li P, Wu NL, Yan Y, et al. 2010. Production of p53 gene knockout rats by homologous recombination in embryonic stem cells. Nature 467: 211-3.
35. Branda CS, Dymecki SM. 2004. Talking about a revolution: The impact of site-specific recombinases on genetic analyses in mice. Dev Cell 6: 7-28.
36. Seibler J, Kleinridders A, Kuter-Luks B, Niehaves S, et al. 2007. Reversible gene knockdown in mice using a tight, inducible shRNA expression system. Nucleic Acids Res 35: e54.
37. Beard C, Hochedlinger K, Plath K, Wutz A, et al. 2006. Efficient method to generate single-copy transgenic mice by site-specific integration in embryonic stem cells. Genesis 44: 23-8.
38. Condeelis J, Weissleder R. 2010. In vivo imaging in cancer. Cold Spring Harb Perspect Biol 2: a003848.
39. Weissleder R, Pittet MJ. 2008. Imaging in the era of molecular oncology. Nature 452: 580-9.
40. Xue W, Zender L, Miething C, Dickins RA, et al. 2007. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445: 656-60.
41. Poueymirou WT, Auerbach W, Frendewey D, Hickey JF, et al. 2007. F0 generation mice fully derived from gene-targeted embryonic stem cells allowing immediate phenotypic analyses. Nat Biotechnol 25: 91-9.
42. Premsrirut PK, Dow LE, Kim SY, Camiolo M, et al. 2011. A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell 145: 145-58.
43. Vafaizadeh V, Klemmt P, Brendel C, Weber K, et al. 2010. Mammary epithelial reconstitution with gene-modified stem cells assigns roles to Stat5 in luminal alveolar cell fate decisions, differentiation, involution, and mammary tumor formation. Stem Cells 28: 928-38.
44. Jackson EL, Willis N, Mercer K, Bronson RT, et al. 2001. Analysis of lung tumor initiation and progression using conditional expression of oncogenic Kras. Genes Dev 15: 3243-8.
45. Aguirre AJ, Bardeesy N, Sinha M, Lopez L, et al. 2003. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17: 3112-26.
46. Hingorani SR, Wang L, Multani AS, Combs C, et al. 2005. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7: 469-83.
47. Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, et al. 2009. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15: 294-303.